Drugs / BMN 333
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07441876 | Apr 2026 → Jun 2029 expected | achondroplasia | BioMarin Pharmaceutical | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | BioMarin Pharmaceutical | Results BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 biomarin.com ↗
New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia |
| 2025-08-04 | BioMarin Pharmaceutical | Results BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS biomarin.com ↗
BMN 333, our long-acting CNP, achieved our targeted profile in the healthy volunteer study and is now expected to move into the pivotal study in 2026. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | BioMarin Pharmaceutical | BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 biomarin.com ↗ |
| 2025-08-04 | BioMarin Pharmaceutical | BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS biomarin.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441876 ↗ |
| Route | Subcutaneous | “Administration: Weekly subcutaneous injection” NCT07441876 ↗ |